socalTECH

APRIL 10, 2012

Thousand Oaks-based biotech giant Amgen said this morning that it has agreed to buy KAI Pharmaceuticals , a developer of treatments for secondary hyperparathyroidism (SHPT) in patients with chronic kidney disease (CKD) who are on dialysis, for $315M in cash. KAI Pharmaceuticals is based in South San Francisco. READ MORE>>.

Thousand Oaks 160

Thousand Oaks Capital Develop Development 160

socalTECH

JANUARY 24, 2011

Thousand Oaks-based biotech giant Amgen said Monday afternoon that it is acquiring Biovex , a Woburn, Massachusetts-based developer of treatments for melanoma and head and neck cancer. BioVex develops OncoVEX, a novel oncolytic vaccine in Phase 3 clinical development. READ MORE>>.

Thousand Oaks 167

Thousand Oaks Sales Invest Capital 167

socalTECH

FEBRUARY 28, 2012

Thousand Oaks-based Ceres , the developer of seed stock for energy crops, said today that it has closed its IPO, selling a total of 5,750,000 shares of its common stock at $13.00 Barclays Capital, Piper Jaffray, Raymond James, and Simmons & Company International. The firm is now trading around $15.08. READ MORE>>.

Thousand Oaks 140

Thousand Oaks Southern California Marketing Capital 140

socalTECH

FEBRUARY 22, 2012

Thousand Oaks-based Ceres , the developer of specialized seeds for the biofuels market, has priced its IPO, saying that it will offer up 5,000,000 shares of its common stock at $13.00 Barclays Capital, PIper Jaffray, Raymond James, and Simmons & Company International.

Pricing 150

Pricing Thousand Oaks Startup Design 150

socalTECH

JANUARY 25, 2012

Thousand Oaks-based Ceres , the developer of seeds to supply the bioenergy and biofuels feedstock business, has set its initial pricing range for its IPO, according to a filing from the company this morning. Barclays Capital, Piper Jaffray, Raymond James, and Simmons & Company International. and $23.00

Pricing 145

Pricing Thousand Oaks Design Capital 145

socalTECH

MAY 23, 2011

Thousand Oaks-based Ceres , the developer of seeds aimed at producing renewable, biomass feedstocks for the biofuels industry, has filed for an IPO. and Barclays Capital. and Barclays Capital. The firm's IPO is being underwritten by Goldman, Sachs & co., The firm said it had a net loss of $22.5M READ MORE>>.

Thousand Oaks 140

Thousand Oaks .Net Capital Marketing 140